[Corrections] Correction to Lancet Oncol 2018; 19: 87 –100

Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19: 87 –100—In table 1, the proportion of Asian patients in the buparlisib plus fulvestrant group (second column) should be 7%. In figure 3, the total number of Asian patients should be 29. In the Results section, the following sentence should have read “In the 11 (13%) cases of discordance, a PIK3CA wild-type tumour sample and PIK3CA-mutated ctDNA were reported in three (4%) patients and PIK3CA mutations detected in the tumour sample but not in ctDNA in seven (9%) patients.” These corrections have been made to the online version as of Feb 28, 2018.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research